… life-saving immunomodulatory therapies. The need for such therapies in COVID-19 is unlikely
… Here, we summarize current knowledge on COVID-19 immunopathogenesis in relation to …

… in severely ill patients with COVID-19. This cascade of events … inflammatory markers in
COVID-19-related complications. … drugs, therapies, and control measures to counter COVID-19. …

… Immunomodulatory therapies that are, in our view, likely to be successful in patients with
COVID-19 are those that are tailored to the patient’s immunophenotype in real time. Further …

… pathology behind COVID-19 is complex … COVID-19, and their contribution to pathogen
clearance and damage to then discuss possible therapeutic options involving immunomodulatory …

Objective Baricitinib seems a promising therapy for COVID-19. To fully-investigate its effects,
we in-vitro evaluated the impact of baricitinib on the SARS-CoV-2-specific-response using …

… COVID-19 disease. There is accumulating evidence that morbidity and mortality in COVID-19 …
into immunomodulatory therapies aimed at targeting the excessive host immune response. …

… Although the role of the immune system in overcoming COVID-19 is … COVID-19 is
presented with a focus on convalescent plasma therapy, antibodies, and immunomodulators…

… such as the use of immunomodulatory drugs. Therefore, we aim to address risk factors and
… of COVID-19 patients with hospital-acquired BSI, focusing on the use of immunomodulatory …

… evidence about immunomodulatory therapies for the management of COVID-19, conclusive
… EULAR initiative to formulate PtC on COVID-19 pathophysiology and immunomodulatory …

… Citation85 have projected to use SARS-CoV-2-specific and HLA-matched cytotoxic T cells
arranged from convalescent COVID-19 patients as need of the hour therapy in COVID 19 …